MapLight Therapeutics Director Makes $441K Stock Purchases as Company Advances Trials
MapLight Therapeutics director George Pavlov purchased common stock worth $441,167 in a sequence of insider transactions on February 18-20, 2026. The purchases took place at weighted average prices between $17.48 and $17.86 per share. The trades coincide with the company announcing an accelerated timeline for topline results from two Phase 2 trials…